Patient-Enhanced Drug Discovery and Development Date Published: Aug 17, 2020 Article This PharmaVoice article argues that patients should be viewed as partners in drug development. While big pharma companies are incorporating the patient experience more in R&D, it’s not in a consistent manner. From informed consent forms and recruitment materials to study design, aspects of a trial can easily be adapted to include patient insights. Find out the mutual benefits to forming relationships with patients and how pharma companies are starting to applying this approach to their clinical trial studies. Contributing industry members include Signant Heath’s Bill Byrom, AstraZeneca’s Helena Chung, and Antidot’s Lindsey Wahlstrom-Edwards. Read More Share: LinkedInTweet Recommended Resources Article Conversation with Bill Byrom & Mariana Fontana: Measuring Aspects of Health in Heart Failure Research Dr. Bill Byrom, Principal, eCOA Science at Signant Health, recently had the pleasure of sitting downwith Professor Marianna Fontana, Professor... Download Now Article Conversation with Bill Byrom & Julian Gillmore: Increasing the Usefulness of COAs in Heart Failure Research Dr. Bill Byrom, Principal, eCOA Science at Signant Health, recently had the pleasure of sitting downwith Professor Julian Gillmore, Professor... Download Now Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now